SShortSingh.
Back to feed

US Government Backs OpenAI in NYT Copyright Fair Use Dispute

0
·49 views

The Trump administration has filed a letter supporting OpenAI in its ongoing copyright lawsuit brought by The New York Times. The government's position aligns with OpenAI's argument that using copyrighted material to train artificial intelligence models constitutes fair use. The case centers on whether AI companies can legally train their systems on third-party intellectual property without permission or compensation. The administration's intervention marks a significant moment, signaling a potentially favorable federal stance toward AI developers in copyright disputes.

Read the full story at WIRED

This is an AI-generated summary. ShortSingh links to the original source for the complete article.

Discussion (0)

Log in to join the discussion and vote.

Log in

Related stories

0
ScienceWIRED ·

WIRED Links 150 Ikea $10 Speakers Into a Giant Wall of Sound

WIRED set out to build a massive sound installation by connecting around 150 of Ikea's inexpensive $10 Bluetooth speakers. The project attempts something the Swedish furniture brand had not tried itself: creating a sonic monolith from large numbers of the cheapest speakers on the market. The experiment raises the question of whether a small, inexpensive product can become impressive when multiplied at scale. The article details the effort as a test of how far the low-cost hardware can be pushed.

0
ScienceWIRED ·

AI Tools Help Expose Years-Old PHP Vulnerabilities, Then Attacks Follow

Security researchers used AI tools to help identify long-standing vulnerabilities in the PHP web scripting language. Shortly afterward, attackers began carrying out AI-assisted attacks exploiting these flaws. The episode highlights how AI can make existing software bugs easier to find and weaponize. The original report is brief, so further details on affected systems and scale are not specified here.

0
ScienceWIRED ·

Personalized mRNA Vaccine Cuts Melanoma Recurrence Risk by Over 40% in Phase 3 Trial

A new mRNA vaccine tailored to each patient's tumor has reduced the risk of melanoma recurrence by more than 40 percent, according to Phase 3 trial results. The findings were reported by WIRED. Because the vaccine is customized to the individual tumor, it represents a personalized approach to cancer treatment. The results add to growing evidence that mRNA vaccine technology may be effective against cancer. The article presents these trial outcomes as a further sign of the technology's potential in oncology.

0
ScienceWIRED ·

Indie Developers Build Quirky Apps for Apple's Foldable iPhone Duo

Apple's first folding phone is prompting independent developers to design playful, unconventional apps. These programs are built to make use of both the expansive screen and the device's hinge. WIRED has compiled a list of nine such apps for users exploring the Duo. The selection highlights how creators are experimenting with the foldable format. The article is aimed at readers who want to discover novel software for the new hardware.

US Government Backs OpenAI in NYT Copyright Fair Use Dispute · ShortSingh